Active surveillance for the management of prostate cancer in a contemporary cohort

Cancer
Marc A Dall'EraPeter R Carroll

Abstract

Active surveillance followed by selective treatment for men who have evidence of disease progression may be an option for select patients with early-stage prostate cancer. In this article, the authors report their experience in a contemporary cohort of men with prostate cancer who were managed with active surveillance. All men who were managed initially with active surveillance were identified through the authors' institutional database. Selection criteria for active surveillance included: prostate-specific antigen (PSA)<10 ng/mL, biopsy Gleason sum </=6 with no pattern 4 or 5, cancer involvement of <33% of biopsy cores, and clinical stage T1/T2a tumor. Patients were followed with PSA measurements and digital rectal examination every 3 to 6 months and with transrectal ultrasound at 6- to 12-month intervals. Beginning in 2003, patients also underwent repeat prostate biopsy at 12 to 24 months. The primary outcome measured was active treatment. Evidence of disease progression, defined as an increase in rebiopsy Gleason sum or significant PSA velocity changes (>0.75 ng/mL per year), was a secondary outcome. Chi-square and log-rank tests were used to compare groups. The association between clinical characteristics and receipt of act...Continue Reading

References

Feb 2, 1994·JAMA : the Journal of the American Medical Association·J I EpsteinC B Brendler
Feb 8, 2002·The Journal of Urology·H Ballentine CarterJonathan I Epstein
Mar 21, 2002·Journal of the National Cancer Institute·Arnold L PotoskyJanet L Stanford
Jul 3, 2003·Journal of the National Cancer Institute·Matthew R CooperbergPeter R Carroll
Oct 29, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Corey A CarterJudd W Moul
Mar 17, 2004·The Journal of Urology·Manish I PatelPeter T Scardino
Jun 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew R CooperbergPeter R Carroll
Jul 13, 2004·The New England Journal of Medicine·Anthony V D'AmicoWilliam J Catalona
Nov 5, 2004·Cancer Nursing·Donald E BaileyJames Mohler
Nov 13, 2004·The Journal of Urology·P EmiliozziV Pansadoro
Jul 28, 2005·JAMA : the Journal of the American Medical Association·Stephen J FreedlandAlan W Partin
Mar 2, 2006·Journal of the National Cancer Institute·Christopher WarlickH Ballentine Carter
Mar 27, 2007·Urology·Stephen J FreedlandUNKNOWN SEARCH Database Study Group
Jul 17, 2007·The Journal of Urology·Ramachandran VenkitaramanChris Parker
Jul 17, 2007·The Journal of Urology·David M LatiniUNKNOWN CaPSURE Investigators
Oct 16, 2007·The Journal of Urology·H Ballentine CarterJonathan I Epstein

❮ Previous
Next ❯

Citations

Dec 2, 2010·JAMA : the Journal of the American Medical Association·Julia H HayesPamela M McMahon
Jan 16, 2013·Current Treatment Options in Oncology·Laurence Klotz
Dec 1, 2009·The Indian Journal of Surgery·Louis S KraneAshok K Hemal
Dec 1, 2010·Nature Reviews. Clinical Oncology·Markos KaravitakisMathias H Winkler
May 5, 2010·Nature Reviews. Clinical Oncology·Peter C Albertsen
Dec 7, 2011·Prostate Cancer and Prostatic Diseases·M A GorinM S Soloway
Jan 19, 2013·Investigative Radiology·Diederik M SomfordUNKNOWN MR-PRIAS Collaboration Group
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William V ShappleyJune M Chan
Dec 1, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew R CooperbergPeter R Carroll
Aug 17, 2010·Clinical Interventions in Aging·Jaspreet SinghLeonard G Gomella
Aug 15, 2012·F1000 Medicine Reports·Laurence Klotz
Apr 9, 2014·Current Opinion in Urology·Laurence Klotz, Mark Emberton
Dec 1, 2009·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·M PeyromaureUNKNOWN CCAFU
May 14, 2014·Nature Reviews. Clinical Oncology·Laurence Klotz, Mark Emberton
May 27, 2009·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·F CornudT Flam
Apr 3, 2013·International Journal of Clinical Oncology·Takahiro InoueTadashi Matsuda
Dec 7, 2010·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·L SalomonUNKNOWN Oncology Committee of the French Association of Urology (CCAFU)
Aug 16, 2014·Biomarkers in Medicine·Mohamed Jalloh, Matthew R Cooperberg
May 28, 2014·Clinical Genitourinary Cancer·Brandon A MahalPaul L Nguyen
Feb 4, 2014·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·L SalomonUNKNOWN Les membres du CCAFU
Jun 15, 2013·Seminars in Radiation Oncology·Shelly X Bian, Karen E Hoffman
Apr 27, 2013·Actas urologicas españolas·V HernándezC Llorente

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Laurence KlotzAndrew Loblaw
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Jeffrey J TosoianH Ballentine Carter
JAMA : the Journal of the American Medical Association
Jonathan I EpsteinC B Brendler
© 2022 Meta ULC. All rights reserved